BAVARIAN NORDIC

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1992-01-01

Employees: 759

Market Cap: $3.1B

Website: http://www.bavarian-nordic.com

Clinical Trials

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Phase 2

Completed

Conditions: Smallpox

Interventions: Biological: FD formulation of IMVAMUNE®
Biological: LF formulation of IMVAMUNE®

First Posted Date: 2012-08-20

Last Posted Date: 2020-10-12

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 651

Registration Number: NCT01668537

Locations: 🇺🇸
PRA, Lenexa, Kansas, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Miami Research Associates, South Miami, Florida, United States

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Phase 1

Completed

Conditions: Cholera

Interventions: Biological: Placebo
Biological: PXVX0200

First Posted Date: 2012-04-25

Last Posted Date: 2023-06-27

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 66

Registration Number: NCT01585181

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Biological: Placebo
Other: GM-CSF Placebo
Drug: GM-CSF

First Posted Date: 2011-03-24

Last Posted Date: 2019-09-04

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 1297

Registration Number: NCT01322490

Locations: 🇺🇸
Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center, Berkeley, California, United States

and more 216 locations

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: MVA-BN-HER2

First Posted Date: 2010-06-29

Last Posted Date: 2019-03-14

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 15

Registration Number: NCT01152398

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Phase 3

Completed

Conditions: Smallpox

Interventions: Biological: IMVAMUNE®
Other: Placebo

First Posted Date: 2010-06-15

Last Posted Date: 2019-01-03

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 4005

Registration Number: NCT01144637

Locations: 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Northern California Clinical Research Center (NCCRC), Redding, California, United States

and more 30 locations

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Phase 2

Completed

Conditions: Measles

Interventions: Biological: MVA-mBN85B
Biological: Rouvax

First Posted Date: 2009-04-30

Last Posted Date: 2012-07-27

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 90

Registration Number: NCT00891007

Locations: 🇿🇦
Chris Hani Baragwanath Hospital, Respiratory and Meningeal Pathogens Research Unit, Bertsham, South Africa

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Phase 2

Completed

Conditions: Smallpox

Interventions: Biological: IMVAMUNE

First Posted Date: 2009-03-06

Last Posted Date: 2019-01-10

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 120

Registration Number: NCT00857493

Locations: 🇺🇸
University of Kentucky, School of Medicine, Department of Medicine, Lexington, Kentucky, United States
🇺🇸
University of Rochester, Medical Center, Rochester, New York, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 1 locations

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Phase 2

Completed

Conditions: Smallpox

Interventions: Biological: IMVAMUNE
Procedure: Blood Draw Only

First Posted Date: 2008-05-30

Last Posted Date: 2019-03-13

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 304

Registration Number: NCT00686582

Locations: 🇩🇪
Harrison Clinical Research Deutschland GmbH, München, Germany

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Phase 1

Completed

Conditions: Androgen-insensitive Prostate Cancer

Interventions: Biological: MVA-BN-PRO

First Posted Date: 2008-03-05

Last Posted Date: 2019-03-13

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 24

Registration Number: NCT00629057

Locations: 🇺🇸
Urology Clinics of North Texas, PA, Dallas, Texas, United States
🇺🇸
Urology Centers of Alabama, Homewood, Alabama, United States
🇺🇸
Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States

and more 4 locations

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: MVA-mBN120B

First Posted Date: 2008-02-26

Last Posted Date: 2010-05-20

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 15

Registration Number: NCT00623259

Locations: 🇺🇸
Washington University, St. Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy